Trade Aclaris Therapeutics Inc - ACRS CFD
Market information is presented
as of 2023-09-21
- Summary
Spread | 0.07 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Aclaris Therapeutics Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 14.01 |
Open* | 14.02 |
1-Year Change* | -1.68% |
Day's Range* | 13.84 - 14.36 |
52 wk Range | 5.77-18.96 |
Average Volume (10 days) | 943.88K |
Average Volume (3 months) | 13.87M |
Market Cap | 535.92M |
P/E Ratio | -100.00K |
Shares Outstanding | 70.79M |
Revenue | 31.17M |
EPS | -1.55 |
Dividend (Yield %) | N/A |
Beta | 0.66 |
Next Earnings Date | Nov 6, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Jun 29, 2022 | 14.32 | 0.74 | 5.45% | 13.58 | 14.37 | 13.50 |
Jun 28, 2022 | 14.01 | -0.96 | -6.41% | 14.97 | 15.26 | 13.98 |
Jun 27, 2022 | 15.06 | 0.68 | 4.73% | 14.38 | 15.72 | 14.38 |
Jun 24, 2022 | 14.41 | -1.42 | -8.97% | 15.83 | 16.16 | 14.17 |
Jun 23, 2022 | 15.81 | 0.28 | 1.80% | 15.53 | 16.17 | 15.13 |
Jun 22, 2022 | 15.43 | 0.01 | 0.06% | 15.42 | 16.16 | 15.41 |
Jun 21, 2022 | 15.93 | 0.35 | 2.25% | 15.58 | 16.52 | 15.58 |
Jun 17, 2022 | 15.57 | 0.97 | 6.64% | 14.60 | 15.84 | 14.60 |
Jun 16, 2022 | 14.76 | 0.77 | 5.50% | 13.99 | 14.88 | 13.99 |
Jun 15, 2022 | 14.72 | 0.89 | 6.44% | 13.83 | 14.80 | 13.80 |
Jun 14, 2022 | 13.95 | 1.16 | 9.07% | 12.79 | 14.00 | 12.65 |
Jun 13, 2022 | 12.91 | -0.88 | -6.38% | 13.79 | 13.99 | 12.41 |
Jun 10, 2022 | 14.39 | -0.22 | -1.51% | 14.61 | 14.90 | 14.17 |
Jun 9, 2022 | 15.04 | 0.06 | 0.40% | 14.98 | 15.48 | 14.98 |
Jun 8, 2022 | 15.42 | 0.41 | 2.73% | 15.01 | 15.86 | 15.01 |
Jun 7, 2022 | 15.39 | 1.36 | 9.69% | 14.03 | 15.45 | 14.03 |
Jun 6, 2022 | 14.71 | -0.02 | -0.14% | 14.73 | 14.94 | 14.44 |
Jun 3, 2022 | 14.70 | 0.48 | 3.38% | 14.22 | 14.90 | 14.08 |
Jun 2, 2022 | 14.41 | 1.06 | 7.94% | 13.35 | 14.94 | 13.35 |
Jun 1, 2022 | 13.32 | 0.66 | 5.21% | 12.66 | 13.43 | 12.59 |
Aclaris Therapeutics Inc Events
Time (UTC) | Country | Event |
---|---|---|
Monday, November 6, 2023 | ||
Time (UTC) 13:30 | Country US
| Event Q3 2023 Aclaris Therapeutics Inc Earnings Release Q3 2023 Aclaris Therapeutics Inc Earnings ReleaseForecast -Previous - |
Wednesday, February 21, 2024 | ||
Time (UTC) 13:30 | Country US
| Event Q4 2023 Aclaris Therapeutics Inc Earnings Release Q4 2023 Aclaris Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 29.752 | 6.761 | 6.482 | 4.227 | 6.151 |
Revenue | 29.752 | 6.761 | 6.482 | 4.227 | 6.151 |
Total Operating Expense | 119.606 | 96.484 | 57.394 | 115.285 | 90.931 |
Selling/General/Admin. Expenses, Total | 25.133 | 23.619 | 20.53 | 27.827 | 25.761 |
Research & Development | 77.813 | 43.813 | 31.731 | 64.899 | 60.841 |
Operating Income | -89.854 | -89.723 | -50.912 | -111.058 | -84.78 |
Other, Net | 2.946 | -1.142 | -0.424 | -2.484 | 2.676 |
Net Income Before Taxes | -86.908 | -90.865 | -51.336 | -113.542 | -82.104 |
Net Income After Taxes | -86.908 | -90.865 | -51.154 | -113.542 | -82.104 |
Net Income Before Extra. Items | -86.908 | -90.865 | -51.154 | -113.542 | -82.104 |
Net Income | -86.908 | -90.865 | -51.015 | -161.354 | -132.738 |
Total Adjustments to Net Income | |||||
Income Available to Common Excl. Extra. Items | -86.908 | -90.865 | -51.154 | -113.542 | -82.104 |
Income Available to Common Incl. Extra. Items | -86.908 | -90.865 | -51.015 | -161.354 | -132.738 |
Diluted Net Income | -86.908 | -90.865 | -51.015 | -161.354 | -132.738 |
Diluted Weighted Average Shares | 65.2139 | 56.7306 | 42.5393 | 41.3239 | 32.9098 |
Diluted EPS Excluding Extraordinary Items | -1.33266 | -1.60169 | -1.20251 | -2.74761 | -2.49482 |
Dividends per Share - Common Stock Primary Issue | |||||
Diluted Normalized EPS | -1.26059 | -1.17267 | -1.20251 | -2.29983 | -2.49482 |
Cost of Revenue, Total | 11.96 | 4.713 | 5.133 | 4.055 | 4.329 |
Gross Profit | 17.792 | 2.048 | 1.349 | 0.172 | 1.822 |
Total Extraordinary Items | 0 | 0 | 0.139 | -47.812 | -50.634 |
Depreciation / Amortization | 0 | 0 | |||
Unusual Expense (Income) | 4.7 | 24.339 | 0 | 18.504 | 0 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 1.869 | 2.528 | 7.753 | 19.018 | 1.528 |
Revenue | 1.869 | 2.528 | 7.753 | 19.018 | 1.528 |
Cost of Revenue, Total | 1.592 | 1.869 | 1.514 | 8.223 | 1.068 |
Gross Profit | 0.277 | 0.659 | 6.239 | 10.795 | 0.46 |
Total Operating Expense | 33.684 | 32.446 | 36.832 | 39.892 | 22.522 |
Selling/General/Admin. Expenses, Total | 8.317 | 8.79 | 7.146 | 5.813 | 6.075 |
Research & Development | 25.275 | 22.587 | 21.072 | 23.656 | 18.779 |
Unusual Expense (Income) | -1.5 | -0.8 | 7.1 | 2.2 | -3.4 |
Operating Income | -31.815 | -29.918 | -29.079 | -20.874 | -20.994 |
Other, Net | 2.246 | 1.758 | 1.444 | 0.922 | 0.462 |
Net Income Before Taxes | -29.569 | -28.16 | -27.635 | -19.952 | -20.532 |
Net Income After Taxes | -29.569 | -28.16 | -27.635 | -19.952 | -20.532 |
Net Income Before Extra. Items | -29.569 | -28.16 | -27.635 | -19.952 | -20.532 |
Total Extraordinary Items | 0 | ||||
Net Income | -29.569 | -28.16 | -27.635 | -19.952 | -20.532 |
Income Available to Common Excl. Extra. Items | -29.569 | -28.16 | -27.635 | -19.952 | -20.532 |
Income Available to Common Incl. Extra. Items | -29.569 | -28.16 | -27.635 | -19.952 | -20.532 |
Diluted Net Income | -29.569 | -28.16 | -27.635 | -19.952 | -20.532 |
Diluted Weighted Average Shares | 70.6335 | 66.8728 | 66.7018 | 66.6753 | 65.99 |
Diluted EPS Excluding Extraordinary Items | -0.41863 | -0.4211 | -0.41431 | -0.29924 | -0.31114 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.43986 | -0.43306 | -0.30786 | -0.26625 | -0.36266 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 231.55 | 205.032 | 57.493 | 83.803 | 179.499 |
Cash and Short Term Investments | 217.571 | 191.414 | 54.131 | 75.015 | 167.972 |
Cash & Equivalents | 45.277 | 27.349 | 22.063 | 35.937 | 57.019 |
Short Term Investments | 172.294 | 164.065 | 32.068 | 39.078 | 110.953 |
Prepaid Expenses | 13.495 | 12.995 | 2.59 | 3.118 | 4.802 |
Total Assets | 254.596 | 251.211 | 70.784 | 98.297 | 275.566 |
Property/Plant/Equipment, Total - Net | 3.779 | 4.772 | 5.783 | 7.203 | 2.287 |
Property/Plant/Equipment, Total - Gross | 10.374 | 9.968 | 9.517 | 9.749 | 3.609 |
Accumulated Depreciation, Total | -6.595 | -5.196 | -3.734 | -2.546 | -1.322 |
Long Term Investments | 12.242 | 34.242 | |||
Other Long Term Assets, Total | 0.052 | 0.117 | 0.385 | 0.092 | 68.003 |
Total Current Liabilities | 21.938 | 22.931 | 14.874 | 22.432 | 27.342 |
Accounts Payable | 10.351 | 9.985 | 5.254 | 9.917 | 14.755 |
Accrued Expenses | 5.979 | 5.082 | 4.574 | 4.015 | 6.071 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 5.608 | 7.864 | 5.046 | 8.389 | 6.374 |
Total Liabilities | 56.975 | 53.87 | 33.134 | 28.385 | 60.442 |
Total Long Term Debt | 0 | 0 | 10.653 | 0.021 | 29.914 |
Other Liabilities, Total | 34.67 | 30.572 | 7.24 | 5.383 | 2.637 |
Total Equity | 197.621 | 197.341 | 37.65 | 69.912 | 215.124 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.001 | 0.001 | 0.00045 | 0.00042 | 0 |
Additional Paid-In Capital | 880.832 | 792.971 | 542.286 | 523.505 | 507.366 |
Retained Earnings (Accumulated Deficit) | -682.315 | -595.407 | -504.542 | -453.527 | -292.173 |
Other Equity, Total | -0.897 | -0.224 | -0.09445 | -0.06642 | -0.069 |
Total Liabilities & Shareholders’ Equity | 254.596 | 251.211 | 70.784 | 98.297 | 275.566 |
Total Common Shares Outstanding | 66.6887 | 61.2285 | 45.1093 | 41.4856 | 41.2107 |
Total Receivables, Net | 0.484 | 0.623 | 0.772 | 0.704 | 0.563 |
Accounts Receivable - Trade, Net | 0.484 | 0.623 | 0.772 | 0.704 | 0.563 |
Goodwill, Net | 0 | 18.504 | |||
Intangibles, Net | 6.973 | 7.048 | 7.123 | 7.199 | 7.273 |
Current Port. of LT Debt/Capital Leases | 0 | 0.111 | 0.142 | ||
Deferred Income Tax | 0.367 | 0.367 | 0.367 | 0.549 | 0.549 |
Total Inventory | 0 | 0 | |||
Other Current Assets, Total | 4.966 | 6.162 | |||
Long Term Debt | 0 | 10.653 | 0 | 29.914 | |
Capital Lease Obligations | 0 | 0.021 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 184.361 | 231.55 | 256.573 | 259.354 | 190.881 |
Cash and Short Term Investments | 170.803 | 217.571 | 248.062 | 248.603 | 179.622 |
Cash & Equivalents | 44.722 | 45.277 | 61.653 | 68.264 | 36.342 |
Short Term Investments | 126.081 | 172.294 | 186.409 | 180.339 | 143.28 |
Total Receivables, Net | 0.686 | 0.484 | 0.597 | 0.637 | 0.633 |
Accounts Receivable - Trade, Net | 0.686 | 0.484 | 0.597 | 0.637 | 0.633 |
Prepaid Expenses | 12.872 | 13.495 | 7.914 | 10.114 | 10.626 |
Total Assets | 229.705 | 254.596 | 267.632 | 277.976 | 226.527 |
Property/Plant/Equipment, Total - Net | 4.546 | 3.779 | 4.021 | 4.343 | 4.531 |
Property/Plant/Equipment, Total - Gross | 11.528 | 10.374 | 10.25 | 10.217 | 10.056 |
Accumulated Depreciation, Total | -6.982 | -6.595 | -6.229 | -5.874 | -5.525 |
Intangibles, Net | 6.954 | 6.973 | 6.992 | 7.011 | 7.03 |
Long Term Investments | 33.602 | 12.242 | 0 | 7.221 | 23.955 |
Other Long Term Assets, Total | 0.242 | 0.052 | 0.046 | 0.047 | 0.13 |
Total Current Liabilities | 18.258 | 21.938 | 19.789 | 16.217 | 16.726 |
Accounts Payable | 8.19 | 10.351 | 7.667 | 5.703 | 8.121 |
Accrued Expenses | 3.237 | 5.979 | 4.596 | 3.626 | 2.9 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 6.831 | 5.608 | 7.526 | 6.888 | 5.705 |
Total Liabilities | 52.895 | 56.975 | 47.794 | 42.224 | 46.328 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Long Term Debt | 0 | ||||
Deferred Income Tax | 0.367 | 0.367 | 0.367 | 0.367 | 0.367 |
Other Liabilities, Total | 34.27 | 34.67 | 27.638 | 25.64 | 29.235 |
Total Equity | 176.81 | 197.621 | 219.838 | 235.752 | 180.199 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 |
Additional Paid-In Capital | 887.638 | 880.832 | 875.982 | 871.805 | 795.366 |
Retained Earnings (Accumulated Deficit) | -710.475 | -682.315 | -654.68 | -634.728 | -614.196 |
Other Equity, Total | -0.354 | -0.897 | -1.465 | -1.326 | -0.972 |
Total Liabilities & Shareholders’ Equity | 229.705 | 254.596 | 267.632 | 277.976 | 226.527 |
Total Common Shares Outstanding | 67.206 | 66.6887 | 66.6796 | 66.6676 | 61.7375 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -86.908 | -90.865 | -51.015 | -161.354 | -132.738 |
Cash From Operating Activities | -67.567 | -52.134 | -38.633 | -96.445 | -100.811 |
Cash From Operating Activities | 0.797 | 0.923 | 1.324 | 6.409 | 1.879 |
Non-Cash Items | 19.739 | 39.151 | 13.6 | 61.203 | 20.61 |
Changes in Working Capital | -1.195 | -1.343 | -2.36 | -2.703 | 9.438 |
Cash From Investing Activities | 12.628 | -167.632 | 6.387 | 105.679 | 9.367 |
Capital Expenditures | -0.605 | -0.308 | -0.453 | -1.613 | -1.356 |
Other Investing Cash Flow Items, Total | 13.233 | -167.324 | 6.84 | 107.292 | 10.723 |
Cash From Financing Activities | 72.867 | 225.052 | 18.372 | -30.316 | 128.261 |
Issuance (Retirement) of Stock, Net | 72.901 | 239.659 | 7.807 | 0.207 | 100.782 |
Net Change in Cash | 17.928 | 5.286 | -13.874 | -21.082 | 36.817 |
Deferred Taxes | 0 | -0.182 | 0 | 0 | |
Financing Cash Flow Items | -0.034 | -3.124 | -0.211 | 28.127 | |
Issuance (Retirement) of Debt, Net | -11.483 | 10.776 | -30.523 | -0.648 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -28.16 | -86.908 | -59.273 | -39.321 | -18.789 |
Cash From Operating Activities | -26.353 | -67.567 | -48.452 | -40.635 | -20.969 |
Cash From Operating Activities | 0.198 | 0.797 | 0.607 | 0.414 | 0.208 |
Non-Cash Items | 6.006 | 19.739 | 7.826 | 1.438 | 1.146 |
Changes in Working Capital | -4.397 | -1.195 | 2.388 | -3.166 | -3.534 |
Cash From Investing Activities | 25.798 | 12.628 | 9.926 | 8.709 | 29.932 |
Capital Expenditures | -0.553 | -0.605 | -0.5 | -0.35 | -0.164 |
Other Investing Cash Flow Items, Total | 26.351 | 13.233 | 10.426 | 9.059 | 30.096 |
Cash From Financing Activities | 0 | 72.867 | 72.83 | 72.841 | 0.03 |
Financing Cash Flow Items | 0 | -0.034 | -0.034 | -0.023 | -0.007 |
Issuance (Retirement) of Stock, Net | 0 | 72.901 | 72.864 | 72.864 | 0.037 |
Issuance (Retirement) of Debt, Net | 0 | ||||
Net Change in Cash | -0.555 | 17.928 | 34.304 | 40.915 | 8.993 |
Deferred Taxes |
Aclaris Therapeutics Inc Company profile
About Aclaris Therapeutics Inc
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing drug candidates for immuno-inflammatory diseases. The Company is focused on leveraging its experience in drug discovery and development and kinase inhibition to develop small molecule therapies to help people impacted immuno-inflammatory conditions. The Company’s drug candidates are Zunsemetinib (ATI-450), ATI-1777 and ATI-2138. The Company’s ATI-450, an investigational oral, small molecule selective MK2 inhibitor compound, for the treatment of rheumatoid arthritis. Its ATI-1777, an investigational topical soft-JAK 1/3 inhibitor compound, for the treatment of atopic dermatitis. The Company is engaged in developing ATI-2138, its investigational oral inhibitor compound, as a potential treatment for T-cell mediated autoimmune diseases. It is also developing oral gut biased JAK inhibitors, as a potential treatment for inflammatory bowel disease.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Aclaris Therapeutics Inc revenues increased 4% to $6.8M. Net loss before extraordinary items increased 78% to $90.9M. Revenues reflect Therapeutics segment increase of 34% to $932K, Contract Research segment increase of 1% to $13.4M. Higher net loss reflects Therapeutics segment loss increase from $31.5M to $67.7M, Corporate segment loss increase of 16% to $20.6M.
Industry: | Biotechnology & Medical Research (NEC) |
640 Lee Rd Ste 200
WAYNE
PENNSYLVANIA 19087-5636
US
News

EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023
Cable coils near lows ahead of Fed and BoE rate decisions
It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.
14:16, 19 September 2023
FTSE 100 Technical Outlook - 18 September 2023
In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.
06:55, 19 September 2023
Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally
The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.
13:46, 15 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com